An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies

Completed

• Conditions: Macular Degeneration
• Interventions: Drug: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)

• Registration Number: NCT03521895
• Lead Sponsor: Bayer

Brief Summary

The aim of this integrated analysis is to describe the effectiveness of Eylea in an integrated pooled analysis using existing individual patient data of two non-interventional studies RAINBOW and PERSEUS.

The primary objective of this integrated analysis is to describe the effectiveness of Eylea on the mean change from baseline in visual acuity (VA) at 12 months in Wet age-related macular degeneration (wAMD) treatment naïve patients.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2018-04-30
• Study First Submitted QC: 2018-04-30
• Study Start: 2018-05-01
• Study First Posted: 2018-05-11
• Primary Completion: 2018-11-30
• Study Completion: 2018-11-30
• Status Verified: 2020-01
• Last Update Submitted: 2020-01-08
• Last Update Posted: 2020-01-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

PERSEUS

• Patients with wet AMD treated with Eylea (in accordance with the local Summary of Product Characteristics, SPC)
• Documentation of at least one Aflibercept (Eylea) injection
• Assessment of at least one visual acuity measurement with available VA letter score for the study eye at baseline and at least one post-baseline assessment of visual acuity with available VA letter score for the study eye and valid for analysis, i.e. measured at least 5 days after an injection RAINBOW
• Patient with a diagnosis of wet AMD will be enrolled after the decision for treatment with Aflibercept (Eylea) has been made
• Patient who meet the local indication criteria for Eylea treatment
• At least one BCVA after the 1st Eylea injection
• BCVA at baseline
• Patient with no history of retinal disease
• Patient not previously treated with any macular laser or any anti-VEGF intravitreal injections for the study eye (for fellow eye allowed).
• For patients with both eyes treated, the eye firstly treated at initial visit will be considered as study eye. If both eyes are treated during initial visit, the treated eye with worst Best-Corrected Visual Acuity (BCVA) at M0 will be retained. If the two conditions are similar the study eye is the Right eye by convention
• Patient with 1st injection of Eylea from 01 January 2014 until 30 April 2015 will be enrolled Exclusion criteria PERSEUS
• Exclusion criteria as listed in the local SPC
• Scar, fibrosis, or atrophy involving the center of the fovea in the study eye
• All patients previously treated with any macular laser or any anti-VEGF intravitreal injections for the study eye will additionally be excluded for this integrated analysis
• Any concomitant therapy with another agent to treat wet AMD in the study eye RAINBOW
• Patient who does not meet the local indication criteria for Eylea treatment. Contraindications listed in the SmPCs must be taken into account
• Patient with another retinal disease: diabetic retinopathy, diabetic macular oedema (DME), myopic choroidal neovascularization, retinal vein occlusion (RVO), central serous chorioretinopathy (CSC), angioid streaks
• Patient who has previously been treated with any macular laser (laser and/or visudyne/PDT) or any anti-VEGF intravitreal injections for the study eye
• Patient taking part in an interventional study at the time of enrolment

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Treatment naïve wAMD	Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)	Treatment naïve patients with wAMD treated with IVT aflibercept from the two underlying studies PERSEUS and RAINBOW

Primary Outcome Measures

Name	Time	Method
Absolute difference in visual acuity (VA) change from baseline will be calculated for each patient as: VA letter score at month 12 - VA letter score at baseline	At baseline and 12 months

Secondary Outcome Measures

Name	Time	Method
Proportion of patients gaining 5, 10 or 15 or more letters	At 12 months
Proportion of patients with ≥70 letters VA	At 12 months
Mean time from diagnosis by the treating physician to start of treatment	At baseline
Proportion of patients with ≥73 letters VA	At 12 months
Proportion of patients losing 5, 10 or 15 or more letters	At 12 months

Trial Locations

Locations (1)

Many locations; 🇩🇪 Multiple Locations, Germany